These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 8779116

  • 1. [The efficacy of the Umex treatment of parkinsonism patients in the initial stage of the disease].
    Fedorova NV, Glozman ZhM, Saltykova NM.
    Ter Arkh; 1995; 67(10):75-7. PubMed ID: 8779116
    [Abstract] [Full Text] [Related]

  • 2. [Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients].
    Stoliarova LG, Kadykov AS, Shvedkov VV, Shakhparonova NV.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):11-3. PubMed ID: 3149842
    [Abstract] [Full Text] [Related]

  • 3. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F.
    Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
    [Abstract] [Full Text] [Related]

  • 4. [Use of iumeks in the combined therapy of parkinsonism patients ].
    Man'kovskiĭ NB, Karaban' IN, Mialovitskaia EA.
    Vrach Delo; 1987 Aug; (8):100-2. PubMed ID: 3120415
    [No Abstract] [Full Text] [Related]

  • 5. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH, Klasser M, Reichmann H.
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [Abstract] [Full Text] [Related]

  • 6. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S, Heinonen E, Hägglund J, Kaugesaar T, Mäki-Ikola O, Palm R, Swedish Parkinson Study Group.
    Neurology; 2006 Apr 25; 66(8):1200-6. PubMed ID: 16540603
    [Abstract] [Full Text] [Related]

  • 7. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP, Boas J.
    Mov Disord; 1997 Mar 25; 12(2):175-82. PubMed ID: 9087975
    [Abstract] [Full Text] [Related]

  • 8. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
    Andreu N, Damase-Michel C, Senard JM, Rascol O, Montastruc JL.
    Mov Disord; 1997 May 25; 12(3):293-6. PubMed ID: 9159721
    [Abstract] [Full Text] [Related]

  • 9. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P, Parkinson-Control Study Group.
    Mov Disord; 2006 Apr 25; 21(4):500-9. PubMed ID: 16267842
    [Abstract] [Full Text] [Related]

  • 10. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
    Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM, Zydis Selegiline Study Group.
    Mov Disord; 2004 Apr 25; 19(4):426-32. PubMed ID: 15077240
    [Abstract] [Full Text] [Related]

  • 11. [Effects of sleep deprivation in patients with parkinsonism].
    Levin IaI.
    Sov Med; 1991 Apr 25; (11):9-11. PubMed ID: 1767333
    [Abstract] [Full Text] [Related]

  • 12. [Present-day treatment of parkinsonism in the aged].
    Siegfried J.
    Schweiz Rundsch Med Prax; 1973 Oct 02; 62(40):1202-3. PubMed ID: 4754539
    [No Abstract] [Full Text] [Related]

  • 13. [Experience using veroshpiron in the combined therapy of parkinsonism].
    Vartanian KZ, Karimova MKh.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1988 Oct 02; 88(12):14-8. PubMed ID: 3245369
    [Abstract] [Full Text] [Related]

  • 14. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ, Swope DM, Dashtipour K.
    Clin Ther; 2007 Sep 02; 29(9):1825-49. PubMed ID: 18035186
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B, Angersbach D, Jost WH.
    Fortschr Neurol Psychiatr; 2007 Apr 02; 75(4):236-41. PubMed ID: 17427044
    [Abstract] [Full Text] [Related]

  • 18. Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.
    Gunzler SA, Pavel M, Koudelka C, Carlson NE, Nutt JG.
    Clin Neuropharmacol; 2009 Apr 02; 32(2):97-102. PubMed ID: 18978495
    [Abstract] [Full Text] [Related]

  • 19. The influence of a previous thalamotomy on the L-dopa effects on mono-manual dexterity in parkinsonism.
    Knutsson E, Mårtensson A, Meyerson BA, Risberg AM.
    Scand J Rehabil Med; 1973 Apr 02; 5(3):130-3. PubMed ID: 4754551
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.